Search
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until … [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidNormethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalThis modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].
Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedCompound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Mixtures: ALINAMIN EX PLUSTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalProduced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular … In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339]
Pipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnIn addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516]. … The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 [T178].
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.
Trifluridine
go.drugbank.com/drugs/DB00432ApprovedInvestigationalIt is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. … cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Pentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawnIt is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160]. … Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate.